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Abstract
 .Recent studies show CCK stimulates tyrosine phosphorylation TYR PHOSP of a number of proteins and evidence from
the pancreas and other cellular systems suggest this could be important in mediating some of CCK’s growth and secretory
effects. In other tissues various neuropeptides such as bombesin can cause tyrosine phosphorylation of p125 focal adhesion
 FAK .kinase p125 and paxillin which are important in mediating their growth effects. The purpose of the present study was
to determine the effects of CCK in rat pancreatic acini on the TYR PHOSP of these latter proteins. In dispersed rat
 .pancreatic acini, cell lysates were incubated with an anti-phosphotyrosine mAb PY20 which was immunoprecipitated and
 . FAKthen analyzed by Western blotting with anti-phosphotyrosine mAb 4G10 , anti-p125 mAb or anti-paxillin mAb. CCK-8
at 5 min increased TYR PHOSP of five proteins of molecular weight )60 000 including a broad M 110–130 000 and Mr r
70–80 000. An increase in TYR PHOSP of both p125FAK and paxillin was detected within 1 min of adding CCK and
reached a maximum at 2.5 min with a 9.1"1.9-fold increase for p125FAK and 3.6"0.6-fold for paxillin. CCK-8 caused a
half-maximal increase in TYR PHOSP of p125FAK at 0.1 nM and paxillin at 0.03 nM. CCK-JMV also stimulated an
increase in TYR PHOSP of both proteins, but was only 50% as efficacious as CCK-8. CCK-JMV caused a half-maximal
increase at 10 nM and maximal at 1 mM for both proteins. To investigate whether the low affinity CCK receptor state also
caused TYR PHOSP of both proteins, increasing concentrations of CCK-JMV were added to a maximally effective CCK-8
 .concentration 1 nM . Detectable inhibition of CCK-8-stimulated TYR PHOSP occurred with 1 mM CCK-JMV and with 3
mM CCK-JMV the CCK-8-stimulated response was inhibited 50% and was the same as that seen with CCK-JMV alone.
These studies demonstrate that in rat pancreatic acini, CCK causes rapid TYR PHOSP of both p125FAK and paxillin. This
stimulation is mediated by both the high affinity and low affinity CCK receptor states. This phosphorylation of these
proteins could be important in mediating CCK’s effect on the cytoskeleton or growth effects as shown for a number of other
 .agents oncogenes, neuropeptides, integrins . q 1997 Elsevier Science B.V.
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1. Introduction
 .Cholecystokinin CCK is a gastrointestinal pep-
w xtide hormone that causes gallbladder contraction 1 ,
w xpancreatic secretion 1,2 , stimulates digestive en-
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w xzyme synthesis 3 , causes enhancement of c-fos,
w xc-jun and c-myc oncogene expression 4 , and has
w xtrophic effects on the pancreas 5 . Extensive studies
show that CCK causes activation of phospholipase C
resulting in hydrolysis of phosphoinositides, genera-
tion of diacylglycerol, and increased inositol 1,4,5-
trisphosphate with subsequent activation of protein
kinase C and release of intracellular calcium and that
these pathways are probably important in mediating
w xmany of the cellular effects of CCK 2 . However,
recent studies suggest that the activation of tyrosine
kinases is probably also an important mediator for
some of the cellular effects of CCK. Recent studies
showed that CCK stimulates tyrosine phosphorylation
of a number of proteins and kinases including JUN
w xkinase and MAP kinase 6–10 . Tyrosine phosphory-
lation has recently been implicated in the action of a
number of neuropeptides that act as potent cellular
growth factors through G protein-coupled receptors
in both mediating their growth effects as well as
w xcytoskeletal changes 11–15 . Bombesin, vasopressin
and endothelin all stimulate tyrosine phosphorylation
of multiple substrates in Swiss 3T3 cells and other
cells, including the novel cytosolic tyrosine kinase
 FAK . w xp125 focal adhesion kinase p125 13,16 and the
w xcytoskeleton-associated protein paxillin 17 , which
w xare associated with focal adhesion plaques 18,19 .
Several investigators have recently reported that
p125FAK and paxillin are also tyrosine phosphory-
w xlated following activation of integrins 20,21 and
w xoncogenes 21 and addition of growth factors like
w xPDGF 22 . Furthermore, recent studies with
bombesin demonstrate activation of this pathway is
necessary to mediate bombesin’s growth effects in
w xSwiss 3T3 cells 23 . Thus tyrosine phosphorylation
of p125FAK and paxillin may represent a point of
convergence in the action of mitogenic neuropep-
w xtides, integrins, oncogenes and growth factors 21 .
The actions of CCK-related peptides are mediated
w xby two different subtypes of CCK receptors 24,25 .
CCK rgastrin receptors, which are found mainly inB
the central nervous system and the gastrointestinal
tract, bind CCK and gastrin with approximately equal
affinity. In contrast, CCK receptors, which are alsoA
present in the gastrointestinal tract and highly local-
ized areas of the central nervous system, exhibit a
500-fold higher affinity for CCK than for gastrin
w x24,25 . A number of recent studies demonstrate that
rat pancreatic acinar cells in contrast to human and
w xguinea pig possess only CCK receptor 26,27 . Re-A
cent studies show this receptor can exist in multiple
w xstates 28–30 , which activate different intracellular
mediators, cause different biological responses and
can be distinguished in rat pancreatic acini by JMV-
w x180, a synthetic analogue of CCK-8 31–33 . Al-
though recent studies show activation of CCK re-B
ceptors stably transfected into fibroblasts can increase
the tyrosine phosphorylation of p125FAK and paxillin
w x34,35 , at present it is unknown whether CCKA
receptor activation in the pancreas or any tissue can
cause tyrosine phosphorylation of p125FAK and pax-
illin. Furthermore, if it causes such changes it will be
important to determine what state of the CCK re-A
ceptor mediates these changes.
The purpose of the present study was to determine
whether activation of the CCK receptor in rat pan-A
creatic acini results in increased tyrosine phosphory-
lation of p125FAK and paxillin; and, to determine
which CCK receptor state is involved in causingA
CCK-induced tyrosine phosphorylation of p125FAK
and paxillin.
2. Materials and methods
2.1. Materials
 .Male Sprague–Dawley rats 150–200 g were ob-
tained from the Small Animals Section, Veterinary
Resources Branch, NIH, Bethesda, MD; purified col-
 .lagenase type CLSPA from Worthington Biochemi-
cals, Freehold, NJ; COOH-terminal octapeptide of
 .cholecystokinin CCK-8 was obtained Bayonne, NJ;
 .phosphate buffer saline PBS , pH 7.4, from Bioflu-
ids, Rockville, MD; anti-focal adhesion kinase
 FAK .p125 monoclonal antibody, anti-paxillin mono-
clonal antibody and anti-phosphotyrosine monoclonal
 .antibody PY20 from Transduction Laboratories,
Lexington, KY; anti-phosphotyrosine monoclonal an-
 .tibody clone 4G10 and recombinant protein A-
agarose from Upstate Biotechnology Inc., Lake
Placid, NY; 12-O-tetradecanoylphorbol-13-acetate
 .TPA , deoxycholic acid from Calbiochem, La Jolla,
 .CA; soybean trypsin inhibitor SBTI , dimethyl sul-
 .foxide DMSO and Triton X-100 from Sigma, St.
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 .Louis, MO; phenylmethanesulfonyl fluoride PMSF
from Fluka, Ronkonkoma, MY; BME amino acids
and BME vitamin solution from Gibco Laboratories,
 .Grand Island, NY; bovine serum albumin BSA
fraction V from Miles Inc., Kankakee, IL; aprotinin,
leupeptin and HEPES from Boehringer Mannheim
Biochemicals, Indianapolis, IN; rabbit anti-mouse IgG
and anti-mouse IgG–horseradish peroxidase conju-
gate, from Pierce, Rockford, IL; sodium dodecyl
 .sulfate SDS , 2-mercaptoethanol, protein assay dye
reagent, TrisrglycinerSDS buffer 10 times concen-
. trated and Trisrglycine buffer 10 times concen-
.trated from BIO-RAD, Richmond, CA; Hyperfilm
ECL, enhanced chemiluminescence detection reagents
from Amersham, Arlington Heights, IL; and nitro-
cellulose membrane from Schleicher and Schuell,
Keene, NH.
Unless otherwise stated, the standard incubation
 .  .solution contained mM : HEPES, 25.5 pH 7.4 ;
NaCl, 98; KCl, 6; NaH PO , 2.5; sodium pyruvate,2 4
5; sodium fumarate, 5; sodium glutamate, 5; glucose,
11.5; CaCl , 0.5; MgCl , 1; glutamine, 2; albumin,2 2
 .  .1% wrv ; trypsin inhibitor, 1% wrv ; vitamin
 .mixture, 1% vrv and amino acid mixture, 1%
 .wrv . The incubation solution was equilibrated with
100% O and all incubations were performed with2
100% O as the gas phase.2
2.2. Methods
2.2.1. Tissue preparation
Dispersed rat pancreatic acini were prepared ac-
w xcording to the modifications 36 of the procedure
w xpublished previously 37 .
2.2.2. Immunoprecipitation
Dispersed acini from one rat were preincubated
with standard incubation solution for 2 h at 378C.
Then dispersed acini were suspended in 15 ml of
 .standard incubation solution and samples 1 ml of
cell suspension were treated with CCK-8 and JMV-
180 at the concentrations and times indicated and
sonicated for 5 s at 48C in 1 ml of a solution
containing 50 mM Tris–HCl, pH 7.5, 150 mM NaCl,
 .1% Triton X-100, 1% deoxycholate, 0.1% wrv
NaN , 1 mM EGTA, 0.4 mM EDTA, 2.5 mgrml3
aprotinin, 2.5 mgrml leupeptin, 1 mM PMSF and 0.2
mM Na VO . Lysates were centrifuged at 15 000 rpm3 4
for 15 min and the amount of protein was measured
in the supernatant. The amount of protein was stan-
dardized to 500 mgrml and 1 ml of the supernatants
were incubated with 4 mg of anti-phosphotyrosine
 .monoclonal antibody PY20 , 4 mg of goat anti-mouse
IgG and 30 ml of protein A–agarose overnight at
48C. The immunoprecipitates were washed three times
Fig. 1. Protein tyrosine phosphorylation in rat pancreatic acinar cells in response to CCK and JMV-180. Acinar cells were incubated in
 .  .the absence or presence of the indicated concentrations of CCK-8 lanes 2 and 3 or JMV-180 lane 4 for 5 min and then lysed. Whole
 .cell lysates were immunoprecipitates with anti-phosphotyrosine monoclonal Ab PY20 . Immunoprecipitates of proteins )60 000
molecular weight were analyzed by SDS-PAGE followed by transfer of proteins to nitrocellulose membrane as described in Section 2.2.
These results are representative of at least three more. Left panel: representative immunoblot with anti-phosphotyrosine monoclonal Ab
 .4G10 . Bands were visualized using ECL. Arrowheads indicate the positions of the main tyrosine phosphorylated proteins )60 kDa in
molecular weight. Middle panel: anti-phosphotyrosine immunoprecipitates were analyzed with a specific anti-p125FAK monoclonal Ab.
Right panel: anti-phosphotyrosine immunoprecipitates were analyzed with an anti-paxillin monoclonal Ab immunoblot.
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with PBS and further analyzed by SDS-PAGE and
Western blotting.
2.2.3. Western blotting
Immunoprecipitates were fractionated by SDS-
PAGE, and the proteins were transferred to nitro-
cellulose membranes. Membranes were blocked
overnight at 48C using blotto 5% non-fat dried milk
in a solution containing 50 mM Tris–HCl, pH 8.0, 2
 .mM CaCl , 80 mM NaCl, 0.05% vrv Tween 20,2
.0.02% NaN . The nitrocellulose membranes contain-3
ing proteins )60 kDa were incubated for 2 h at
258C with 1 mgrml anti-phosphotyrosine mono-
 . FAKclonal antibody 4G10 or with 1 mgrml anti-p125
monoclonal antibody or with 0.1 mgrml anti-paxillin
monoclonal antibody. The membranes were washed
twice for 10 min with blotto and incubated for 40
min at 258C with anti-mouse IgG-horseradish peroxi-
dase conjugate. The membrane were finally washed 2
  .times for 10 min 80 mM NaCl, 0.05% vrv Tween
.20, 0.02% NaN , incubated with enhanced chemilu-3
 .minescence detection reagents ECL for 60 s and
exposed to Hyperfilm ECL for less than 5 min. The
density of bands on the film were measured using a
scanning densitometer Molecular Dynamics, Sunny-
.vale, CA .
Fig. 2. Time-course of CCK-8 and JMV-180 stimulation of p125FAK and paxillin tyrosine phosphorylation in rat pancreatic acinar cells.
Rat pancreatic acinar cells were treated for various times as indicated with 10 nM CCK-8 or 1 mM JMV-180 and then lysed. Whole cell
 .lysates were immunoprecipitates with anti-phosphotyrosine monoclonal Ab PY20 . Immunoprecipitates were analyzed by SDS-PAGE
followed by transfer of proteins to nitrocellulose membrane. Proteins greater than 60 kDa were assessed by anti-p125FAK or anti-paxillin
immunoblotting as described in Section 2.2. Bands were visualized using ECL and quantification of phosphorylation was performed by
scanning densitometry. Left panel: time-course of CCK-8 and JMV-180 stimulation of p125FAK tyrosine phosphorylation. The top two
panels show results from a representative experiment with both CCK-8 and JMV-180. These results are representative of at least three
others. The values shown in the lower panel are the mean"S.E. of four independent experiments and are expressed as fold increase
 .experimentalrcontrol . Right panel: time-course of CCK-8 and JMV-180 stimulation of paxillin tyrosine phosphorylation. The top two
panels show results from a representative experiment with both CCK-8 and JMV-180. These results are representative of at least three
others. The values shown in the lower panel are the mean"S.E. of four independent experiments and are expressed as fold increase
 .experimentalrcontrol .
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3. Results
Treatment of acinar cells with 0.1 nM and 10 nM
CCK causes a marked increase in the tyrosine phos-
phorylation of at least five proteins with molecular
weights )60 kDa, which was the range examined in
 .the present study Fig. 1 . The apparent molecular
masses of these proteins was 170, 145, 126, 95 and
79 kDa these will be referred to as p170, p145,
.p126, p95 and p79 as revealed by immunoprecipita-
tion of pancreatic acinar cells lysates with anti-phos-
 .photyrosine monoclonal antibody PY20 followed
by Western blotting of the immunoprecipitates using
a second anti-phosphotyrosine monoclonal antibody
 .  .4G10 Fig. 1, left panel, lanes 2 and 3 .
To investigate whether the recently identified tyro-
sine kinase p125FAK can serve as a substrate for
CCK-stimulated tyrosine phosphorylation, pancreatic
acinar cells were incubated with 0.1 nM and 10 nM
CCK for 5 min, and lysates of the CCK-treated cells
were immunoprecipitated with anti-phosphotyrosine
 .monoclonal antibody PY20 and the immunoprecipi-
tates were analyzed by Western blotting with specific
FAK anti-p125 monoclonal antibody. Fig. 1 middle
.  .panel shows that CCK lanes 2 and 3 caused a
striking increase in the tyrosine phosphorylation of a
single anti-p125FAK immunoreactive band. This tyro-
sine phosphorylated band exactly co-migrated with
the protein band of 126 kDa obtained by immuno-
precipitation with anti-phosphotyrosine from parallel
cell lysates followed by immunoblot analysis using
anti-phosphotyrosine Fig. 1, left panel, lanes 2 and
.3 .
To determine whether the cytoskeleton-associated
protein paxillin was a constituent of the p79 phospho-
tyrosine-containing band, pancreatic acinar cells
lysates were immunoprecipitated with anti-phospho-
 .tyrosine monoclonal antibody PY20 followed by
immunoblotting with anti-paxillin monoclonal anti-
 .  .body Fig. 1, right panel . CCK 0.1 nM and 10 nM
Fig. 3. Concentration-dependence of CCK-8 and JMV-180 to stimulate p125FAK and paxillin tyrosine phosphorylation in rat pancreatic
acinar cells. Rat pancreatic acinar cells were treated with various concentration of CCK-8 and JMV-180 as indicated for 5 min and then
lysed. p125FAK and paxillin tyrosine phosphorylation were determined by immunoprecipitation and Western blotting as described in Fig.
FAK  .  .2 legend. The top two panels show p125 tyrosine phosphorylation left panel and paxillin tyrosine phosphorylation right panel .
The results are from a single experiment with no additions or with various concentrations of CCK-8 or JMV-180. These results are
FAK  .representative of at least three others. The bottom panel shows the quantification of p125 tyrosine phosphorylation left panel and
 .  .paxillin tyrosine phosphorylation right panel . Values are the means"S.E. ns4 expressed as the percentage of maximal increase
caused by 10 nM CCK-8 above control unstimulated values.
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caused a striking increase in the amount of paxillin
immunoreactivity in anti-phosphotyrosine immuno-
precipitates, which migrated as a broad, diffuse band
of M 72 000–87 000 Fig. 1, right panel, lanes 2 andr
.3 . This band exactly co-migrated with the p79 com-
ponent revealed by anti-phosphotyrosine immuno-
blotting of anti-phosphotyrosine immunoprecipitates
 .Fig. 1, left panel, lanes 2 and 3 .
Tyrosine phosphorylation of p125FAK was a rapid
consequence of addition of 10 nM CCK-8 to pancre-
atic acinar cells. An increase in tyrosine phosphoryla-
tion was detected 1 min after addition of the peptide,
reached a maximum within 2.5 min with a 9.1"1.9-
fold increase, and decreased after 10 min Fig. 2, left
.panel . Moreover, CCK-8 stimulated a rapid increase
in paxillin tyrosine phosphorylation which reached
maximum at 2.5 min with a 3.6"0.6-fold increase
and was maintained for at least 40 min Fig. 2, right
.panel .
The effect of CCK on p125FAK and paxillin tyro-
sine phosphorylation was concentration-dependent. At
a 10 pM concentration, CCK-8 caused a 10% in-
crease in tyrosine phosphorylation, a half-maximal
effect occurred at 0.03"0.015 nM for paxillin tyro-
sine phosphorylation and 0.1 nM for p125FAK and a
maximal effect occurred at 1 nM for both p125FAK
 .and paxillin tyrosine phosphorylation Fig. 3 .
JMV-180 is reported to be an agonist at the CCKA
high-affinity receptor state and an antagonist at the
low affinity CCK -receptor state in rat pancreaticA
w x  .acinar cells 31–33 . JMV-180 1 mM induced tyro-
sine phosphorylation of several cellular proteins as
Fig. 4. Ability of the CCK specific receptor antagonist, L-364,718, to alter CCK-8- and JMV-180-stimulated p125FAK and paxillinA
tyrosine phosphorylation in rat pancreatic acinar cells. Rat pancreatic acinar cells were treated with various concentrations of CCK-8 and
JMV-180 either in the absence or presence of the specific CCK receptor antagonist L-364,718 as indicated for 5 min and then lysed.A
p125FAK and paxillin tyrosine phosphorylation were determined as described in the legend to Fig. 2. Left panel: effect of the CCKA
receptor antagonist, L-364,718 on CCK-8- and JMV-180-stimulated p125FAK tyrosine phosphorylation. The top panel shows results from
a representative experiment of at least three others. The bottom panel shows the phosphorylation of p125FAK expressed as the percentage
 .of maximal increase caused by 10 nM CCK-8 above the control unstimulated values. Values are means"S.E. ns4 . Right panel:
effect of the CCK receptor antagonist, L-364,718 on CCK-8- and JMV-180-stimulated paxillin tyrosine phosphorylation. The top panelA
shows results from a representative experiment of at least three others. The bottom panel shows the phosphorylation of paxillin expressed
 .as the percentage of maximal increase caused by 10 nM CCK-8 above the control unstimulated values. Values are means"S.E. ns4 .
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detected by immunoblotting with anti-phospho-
tyrosine monoclonal antibody Fig. 1, left panel, lane
.4 . The major JMV-180-stimulated tyrosine phospho-
rylated proteins exactly co-migrated with the bands
obtained with CCK-8 stimulation Fig. 1, left panel,
.lane 3 . Moreover, JMV-180 caused a striking in-
crease in the tyrosine phosphorylation of p125FAK
 . Fig. 1, middle panel, lane 4 and paxillin Fig. 1,
.right panel, lane 4 .
An increase in tyrosine phosphorylation of both
p125FAK and paxillin was detected within 1 min of
adding JMV-180 and reached a maximum at 2.5 min
with a 4.7"0.9-fold increase in p125FAK tyrosine
phosphorylation and 3.6"0.8-fold increase for pax-
 .illin Fig. 2 . The magnitude of tyrosine phosphoryla-
tion of p125FAK caused by CCK-8 but not JMV-180
 .Fig. 1 decreased after 2.5 min, whereas for both
peptides the magnitude of tyrosine phosphorylation
 .of paxillin remained relatively stable Fig. 2 . JMV-
180 caused a detectable increase at 0.3 nM, half
maximal effect at 10 nM and maximal effect at 0.1
mM in both p125FAK and paxillin tyrosine phospho-
 .rylation Fig. 3 .
The specific CCK receptor antagonist, L-364,718A
 .1 mM had no effect on tyrosine phosphorylation of
FAK p125 or paxillin when added alone Fig. 4, lane 2,
.left and right panels , but completely inhibited
FAK  .p125 Fig. 4, lanes 4, 6, 8 and 10, left panel and
paxillin tyrosine phosphorylation Fig. 4, lanes 4, 6, 8
. and 10, right panel in response to CCK-8 0.1 nM
.  .and 10 nM and to JMV-180 10 nM and 1 mM .
Because JMV-180-stimulated p125FAK and pax-
illin tyrosine phosphorylation did not attain the full
response that was obtained by CCK-8, we tested both
Fig. 5. Effect of CCK-8 and JMV-180 alone or in combination on p125FAK and paxillin tyrosine phosphorylation. Acini were stimulated
with 3 mM JMV-180, with 1 nM CCK-8 alone or with 1 nM CCK-8 with various concentrations of JMV-180 for 5 min and then lysed.
p125FAK and paxillin tyrosine phosphorylation were determined as described in the legend to Fig. 2. The top panels show results from a
FAK  .  .representative experiment. The bottom panels shows the results of p125 left panel and paxillin right panel tyrosine phosphoryla-
tion and the results are expressed as the percentage of the maximal increase caused by 1 nM CCK-8. Values are means"S.E. for four
experiments. Asterisk indicates significant differences as compared to 1 nM CCK-8 in combination with 0.1 mM JMV-180 P-0.05
.with Student’s t-test for unpaired samples .
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analogues in combination. Acini were stimulated with
3 mM JMV-180 alone Fig. 5, lane 3, left and right
. panel and with 1 nM CCK-8 Fig. 5, lane 2, left and
.right panel alone or in combination with different
concentrations of JMV-180 0.1 mM, 1 mM and 3
.  .mM Fig. 5, lanes 4, 5 and 6, left and right panel .
Inhibition of CCK-8-stimulated p125FAK and paxillin
tyrosine phosphorylation was noted with 1 mM JMV-
 . 180 ns4, P-0.01 Fig. 5, lane 5, left and right
.panel . With 3 mM JMV-180, CCK-8-stimulated ty-
rosine phosphorylation decreased to the same level as
 . that of 3 mM JMV-180 alone ns4, P-0.01 Fig.
.5, lane 6, left and right panel .
4. Discussion
In the present study, we demonstrate that activa-
tion of the CCK receptor in rat pancreatic acinarA
cells causes tyrosine phosphorylation of at least five
proteins of molecular weight )60 000, and demon-
strate for the first time that two of these proteins are
the novel tyrosine kinase p125FAK and the cyto-
skeletal-associated protein, paxillin. Furthermore, we
demonstrate that tyrosine phosphorylation of both
proteins is mediated by activation of both the high
affinity and the low affinity states of the CCKA
receptor.
Recent studies show a number of neuropeptides,
whose receptors have no intrinsic tyrosine kinase
activity, can stimulate tyrosine phosphorylation
w x11,12,14,15 . In previous studies, CCK-8 has been
shown to cause tyrosine phosphorylation of a number
w xof proteins 6–10 ; however, except for the MAP
w x  mapk mapk. kinases 6 p42 and p44 , MEK kinases p43
. w x and p44 10 , and c-Jun amino-terminal kinases p46
. w xand p55 9 , none of the higher molecular weight
w xproteins have been identified 6 . Furthermore, activa-
tion of the CCK receptor transfected into mouseB
w x w x3T3 cells 35 and into rat 1 fibroblasts 34 causes
tyrosine phosphorylation of p125FAK, paxillin and
MAP kinase. Similarly, the neuropeptides, bombesin,
vasopressin, endothelin and bradykinin cause tyrosine
phosphorylation of p125FAK and paxillin in a number
w xof tissues 11,12,14,15 .
w xRecent studies 15,16,38 suggest tyrosine phos-
phorylation of p125FAK and paxillin may be particu-
larly important in mediating the effects of a number
of neuropeptides, oncogenes and integrins particu-
w xlarly on growth 21 . A number of results in our study
support the conclusion that CCK receptor activationA
in rat pancreatic acinar cells can cause tyrosine phos-
phorylation of both of these proteins. First of all,
whether a mouse anti-phosphotyrosine monoclonal
antibody is used initially followed by protein identifi-
cation using anti-p125FAK or anti-paxillin monoclonal
antibodies, or when the antibodies are used in reverse
order, each combination demonstrated tyrosine phos-
phorylation of both of these proteins. Secondly, this
phosphorylation was mediated by the CCK receptorA
because it was inhibited by the specific CCK recep-A
w xtor antagonist, L-364,718 36 . Thirdly, the dose-re-
sponse curve for tyrosine phosphorylation of both
proteins occurred over the same CCK-8 concentra-
tions that cause CCK receptor activation and overA
which CCK-8 stimulates changes in cellular calcium
w x w3 x w x32,39,40 , H thymidine incorporation 41 and
w xMAP kinase activation 6 .
Our results show similarities and differences of the
ability of CCK receptor activation to cause tyrosineA
phosphorylation of these two proteins compared to
w xthe ability of CCK receptor activation 34,35 or theB
ability of other neuropeptides to cause tyrosine phos-
w xphorylation of both these proteins 13,16,17 . Similar
to CCK , increase in p125FAK and paxillin tyrosineB
phosphorylation was rapid, being detected as early as
1 min after addition of the peptide and reaching a
maximum within 2–5 min. The CCK and the CCKA B
receptors differ in the potency of CCK-8 at each
receptor for causing tyrosine phosphorylation of both
proteins. Specifically, the dose-response curve of
p125FAK and paxillin tyrosine phosphorylation in re-
sponse to CCK receptor activation was one log unitA
to the left of that for activation of the CCK recep-B
tor, with the result that lower concentrations of CCK-8
caused significantly more stimulation at the CCKA
than at the CCK receptors. However, CCK recep-B A
tor activation stimulates p125FAK and paxillin tyro-
sine phosphorylation at concentrations that closely
parallel those required to enhance the tyrosine phos-
phorylation of both proteins by bombesin in Swiss
w x3T3 cells 16 . The CCK receptor resembles theA
CCK receptor, but not the GRP receptor, withB
w 2qxregard to their ability to cause changes in Ca andi
stimulate tyrosine phosphorylation of p125FAK and
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paxillin. Similar to the CCK receptor, the CCK-8B
w 2qxdose-response curve for Ca mobilizationi
w x FAK32,40,42 was similar to that seen for p125 and
paxillin tyrosine phosphorylation; however, with the
GRP receptor activation the bombesin dose-response
w 2qxcurve for Ca mobilization was 0.5 log unit to thei
right of that for tyrosine phosphorylation of both
w xproteins in Swiss 3T3 cells 16,43 .
Numerous studies demonstrate that the pancreatic
CCK receptor exists in at least two binding statesA
w x w x24,28–30,33 . In one study 40 in which both states,
a high affinity and a low affinity state, were de-
scribed, each state had a different set of second
messengers and different biological effects. In a num-
w xber of studies 31–33,39 , JMV-180 is reported to
distinguish between these two states in rat pancreatic
acini. Because of this ability, this peptide has been
used to establish that CCK causes pancreatitis by the
w xlow affinity state 44 , stimulates pancreatic growth
w xby high affinity state or by both states 44,45 , causes
enhancement of expression of transcriptional factors
such as c-myc, c-jun and c-fos by the low affinity
w xstate 4 and causes desensitization of stimulated pan-
w xcreatic enzyme secretion by low affinity state 46 . A
number of results in our study support the conclusion
that CCK-8 can cause tyrosine phosphorylation of
p125FAK and paxillin through both the high and low
CCK affinity states. First of all, JMV-180 at 1 nM to
1 mM stimulates tyrosine phosphorylation of both
p125FAK and paxillin, and causes 50% of the maxi-
mal stimulation caused by CCK-8 indicating that the
high-affinity state of the CCK-receptor can cause
tyrosine phosphorylation. Secondly, JMV-180 inhib-
ited the p125FAK and paxillin tyrosine phosphoryla-
tion caused by a maximally effective concentration of
CCK-8. This shows that JMV-180 can antagonize
60% of the ability of CCK-8 to cause tyrosine phos-
phorylation of both these proteins. The ability of
JMV-180 to inhibit the additional increase caused by
CCK-8 over JMV-180 and the fact that this only
occurs at high CCK-8 concentrations, indicate that
occupation of the low-affinity CCK-receptor state by
CCK-8 also produces an additional stimulatory effect
on tyrosine phosphorylation of p125FAK and paxillin.
Thirdly, CCK-8-stimulated tyrosine phosphorylation
of these two proteins occurred over a wide CCK-8-
concentration range with a maximal effect at 1 nM.
This wide range occurs over the concentration range
for CCK-8 occupation of both CCK receptor states,A
the high affinity state and the low affinity state
w x24,28,32,33 .
The cellular function caused by the tyrosine phos-
phorylation of p125FAK and paxillin by activation of
the CCK receptor has not been addressed in thisA
study. With other neuropeptides, such as bombesin,
numerous studies demonstrate the tyrosine phospho-
rylation of both these proteins is particularly impor-
tant in mediating both the effects on cellular mor-
phology, such as actin stress fibre formation and
w xfocal adhesion assembly and on growth 21,23 . In
preliminary studies we found that carbachol also
caused tyrosine phosphorylation of p125FAK and pax-
 .illin in rat pancreatic acini data not shown . Carba-
chol, in contrast to CCK, has minimal trophic effects
w xon rat pancreas or pancreatic acini 47–50 . This
observation raises the possibility that in contrast to
the essential role of these proteins in mediating the
growth effect of bombesin in Swiss 3T3 cells, with
CCK and carbachol they may have a cellular function
independent of growth. Stimulation with supramaxi-
mally effective concentrations of the CCK-analogue,
caerulein, caused marked changes in the apical cyto-
w xskeleton of pancreatic acini 51 , and in vivo causes a
progressive disassembly and degradation of pancre-
w xatic acinar cell microtubules and microfilaments 52 .
At present, whether tyrosine phosphorylation of
p125FAK and paxillin is involved in these CCKA
receptor activation effects on cellular morphology or
whether tyrosine phosphorylation of these proteins
could be involved in CCK-8 mediated secretion is
unknown. Recently, a possible role of tyrosine phos-
phorylation in the regulation of pancreatic secretion
stimulated by CCK has been proposed. These studies
w x7,8,53 found that CCK-8 enhanced tyrosine phos-
phorylation in pancreatic acini and that genistein or
various tyrphostins, two widely used tyrosine kinase
inhibitors, inhibited both CCK-8-stimulated tyrosine
phosphorylation and amylase release. Moreover, these
studies attempted to localize the steps in the
stimulus-secretion pathway that are affected by tyro-
sine kinase inhibition, showing that CCK-8-, NaF- or
GTPg S-stimulated polyphosphoinositides hydrolysis
and calcium ionophore-stimulated amylase release
were significantly inhibited by tyrosine kinase in-
w xhibitors 7,8,53 . In contrast, genistein had no influ-
ence on the secretory response seen with the PKC
( )L.J. Garcia et al.rBiochimica et Biophysica Acta 1358 1997 189–199198
w xactivator, TPA 7,8 . These results indicate that tyro-
sine kinase is involved in at least two separate stages
in the CCK-induced amylase release, one upstream of
PI hydrolysis and one downstream of increased
w 2qx FAKCa . Whether tyrosine phosphorylation of p125i
and paxillin is involved in mediating some of these
effects is at present unknown.
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